Important: Human evidence is limited to small pharmacodynamic studies. No large randomized controlled trials have established efficacy for anti-aging, body composition, or any indication in healthy adults. The 2002 FDA withdrawal was commercial, not safety-related, but it means no active NDA exists. All current use outside pediatric GH deficiency is off-label or research-grade.
Overview
Sermorelin is a synthetic analog of endogenous growth hormone-releasing hormone (GHRH) comprising the biologically active N-terminal 29 amino acids of the 44-residue native peptide. It is the shortest GHRH fragment that retains full receptor-binding activity at the GHRH receptor (GHRHR). Unlike exogenous growth hormone, which bypasses the pituitary entirely, sermorelin preserves the normal hypothalamic-pituitary-somatotroph feedback loop: it stimulates pulsatile GH release while somatostatin feedback remains intact, preventing the tonic GH elevation associated with exogenous GH administration. Sermorelin was FDA-approved for pediatric GH deficiency (1997) and voluntarily withdrawn in 2002 for commercial reasons unrelated to safety, giving it a longer regulatory and clinical history than most research peptides in this catalog.
Mechanism of Action
Sermorelin binds to the GHRH receptor (GHRHR), a Gs-coupled GPCR expressed on somatotroph cells in the anterior pituitary. Receptor activation stimulates adenylyl cyclase, elevating intracellular cAMP and activating protein kinase A (PKA). PKA phosphorylates the transcription factor CREB, which drives transcription of the GH gene and stimulates GH secretion. The short half-life of sermorelin (~10–20 minutes) means its action is transient, producing discrete GH pulses rather than sustained GH elevation. This pulse pattern is critical: physiological GH pulsatility is required for normal IGF-1 production and avoids the receptor downregulation associated with continuous GH stimulation. Somatostatin (SRIF), released from the hypothalamus in counterbalance to GHRH, remains functional throughout, providing the normal feedback brake on GH secretion.
Research Evidence
- Historical FDA approval for pediatric GH deficiency (1997); voluntarily withdrawn 2002 for commercial reasons, not safety
- Stimulates pulsatile GH release via GHRHR/cAMP/PKA/CREB cascade while preserving somatostatin feedback
- Vittone et al. (1997, Metabolism): nightly sermorelin increased IGF-1 and improved body composition in elderly men over 6 months (n=16)
- Walker RF (2006, Clin Interv Aging): reviewed as a physiological approach to adult GH insufficiency with favorable tolerability profile
- Shortest GHRH fragment with full receptor activity (29 AA); half-life ~10–20 min produces discrete GH pulses, not tonic elevation
Bottom line: Sermorelin has the most established safety profile of any GHRH analog in this catalog, backed by a historical FDA approval and decades of clinical use in pediatric GH deficiency. Its axis-preserving mechanism is well-characterized and scientifically sound. Human evidence for adult anti-aging or body composition endpoints is limited to small pharmacodynamic studies — no large outcome RCTs exist. It remains a research compound for adult applications.
Research Protocols & Dosage
Evidence-based research protocols, administration routes, and dosage considerations for Sermorelin are detailed in the full compound profile. See also: Dosage guide for Sermorelin.
Sourcing & Quality
Sermorelin is available from Purgo Labs with third-party COA verification and research-grade purity standards. View Sermorelin at Purgo Labs.